Prelude Capital Management, LLC Lyell Immunopharma, Inc. Transaction History

Prelude Capital Management, LLC

  • $1.57 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024
BUY
$1.71 - $3.07 $13,338 - $23,946
7,800 Added 44.56%
25,304 $56,000
Q4 2023

Feb 14, 2024
BUY
$1.39 - $2.35 $24,330 - $41,134
17,504 New
17,504 $33,000
Q2 2023

Aug 14, 2023
SELL
$1.89 - $3.86 $34,484 - $70,429
-18,246 Reduced 58.86%
12,754 $40,000
Q1 2023

May 15, 2023
BUY
$1.97 - $3.58 $61,070 - $110,980
31,000 New
31,000 $73,000

Others Institutions Holding LYEL

# of Institutions
121
Shares Held
142M
Call Options Held
18.1K
Put Options Held
200
View Full List

About Lyell Immunopharma, Inc.

LYEL Quotes by TradingView
  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $151M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email